Νέα

TIF continues the efforts to address the questions and concerns of its global patients’ and healthcare professionals’ community about the COVID-19 Pandemic and, in doing so, it has issued 2 brand new informational documents. The TIF-proposed Haemoglobinopathy Patient Pathway for Day Care Centres, Units and Clinics treating patients with thalassaemia ...

An unprecedented collaboration across government, academia, private sector, and philanthropy is taking place as a response to the coronavirus global crisis. Today, a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture, and delivery of vaccines, diagnostics, and treatments for COVID-19. The life sciences industry ...

  Global regulators have published a report today presenting the outcomes of a workshop on COVID-19 vaccine development that was convened under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA). This report was the outcome of March 18th first global regulators meeting, chaired jointly by the the ...

Therapeutic advances in β-thalassaemia have gradually led to a significant improvement in prognosis over the past few decades. As a result, patients living in areas where disease specific programmes offer access to modern therapies, experience a new era of prolonged survival that tends to reach that of the normal population. ...

  On Friday, 20 March, Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. When supported for use in COVID-19 ...

During these difficult and challenging times the coronavirus (COVID-19) pandemic is creating at a global level, individuals with underlying medical conditions, such as blood disorders, heart disease, chronic liver disease, endocrine disorders or patients with a compromised immune system, may face an increased risk of  COVID-19 infection, according to the ...

The coronavirus presents many uncertainties, and none of us can completely eliminate the risk of getting infected with COVID-19. Nevertheless, one thing we can do is eat as healthy as possible! In addition to the well-known personal hygiene and preventive measures against the new coronavirus (COVID-19), we can also follow ...

  As the new coronavirus continues to spread affecting an increasing number of countries around the globe and in response to FDA’s Important Information for Blood Establishments Regarding the Novel Coronavirus (COVID-19) Outbreak (FDA Communication), AABB has recently developed a useful toolkit with important information about coronavirus and blood donation, in ...

FT-4202, a potential disease-modifying oral treatment for sickle cell disease being developed by Forma Therapeutics, has been given fast track and rare pediatric disease designations by the U.S. Food and Drug Administration (FDA). A fast track status is meant to accelerate the development and review of the treatment, facilitating discussions with the FDA and enabling the therapy ...

  Observed every year on the last day of February and in the 29th of February in 2020, Rare Disease Day seeks to raise awareness among the general public, as well as policymakers, public authorities, industry representatives, scientists, and health professionals about the more than 7,000 rare disorders that affect as many ...